Savannah State University Office of Graduate Studies and Sponsored Research

Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham

Retrieved on: 
Monday, June 12, 2023
Research, Hospitals, Neurology, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Partnership, Employment, Drug development, Therapy, BIC, Savannah State University Office of Graduate Studies and Sponsored Research, Cancer, Inflammation, CNS, Patient, Mass, Nobel, Mass General Brigham, Growth, Autoimmunity, Pharmaceutical industry, Simcere Pharmaceutical

“The discoveries resulting from this agreement could further advance potentially game-changing technology to the front lines of care in three areas of rapid clinical advancement and high patient need -- neurology, oncology, and inflammation and immunology,” said Chris Coburn, chief innovation officer at Mass General Brigham. “We’re excited to collaborate with industry partners such as Simcere, whose expanding presence in the Boston area is reflective of our region’s continued growth as a biotech hub.”

Key Points: 
  • Simcere Pharmaceutical Group Limited (2096.HK) (Simcere) announced a Sponsored Research Agreement with Mass General Brigham.
  • Under the agreement up to eight research groups at Mass General Brigham will be funded on select projects over the course of two years.
  • By partnering with Mass General Brigham, Simcere gains access to cutting-edge research and leading clinical capabilities which will help accelerate the company's global R&D efforts.
  • "We believe that this Sponsored Research Agreement with Mass General Brigham represents a significant step forward in our efforts to develop innovative new treatment options for patients around the world,” said Zhou Gaobo, Chief Investment Officer, Simcere Pharmaceutical Group.

Milestone in development of state-of-the-art compact plasma accelerators as TAU Systems signs a suite of key agreements with The University of Texas at Austin

Retrieved on: 
Thursday, February 2, 2023
Terawatt, Science, Biotechnology, License, Laboratory, Lawrence Berkeley National Laboratory, TAU, Acceleration, University, Bella Center Copenhagen, Ultraviolet, Research, Discovery, Partnership, Bella, Savannah State University Office of Graduate Studies and Sponsored Research, Television, Pharmaceutical industry, University of Texas at Austin

Led by experts in laser-driven particle accelerators, TAU is democratizing accelerator access for the progress of biotechnology, nuclear and battery technology, and more.

Key Points: 
  • Led by experts in laser-driven particle accelerators, TAU is democratizing accelerator access for the progress of biotechnology, nuclear and battery technology, and more.
  • The Sponsored Research Agreement enables TAU Systems and UT Austin personnel to work together in laboratories and collaborate on researching the fundamental elements of laser-plasma interaction.
  • TAU will fund UT Austin laboratory staff in exchange for shared access to UT Austin laboratories, including TAU personnel working in the capacity of UT Austin research affiliates.
  • As part of the agreement, UT Austin has been issued shares in TAU Systems.

Leonardo DRS Announces Appointment of Dr. Reginald Brothers to Board of Directors

Retrieved on: 
Friday, December 23, 2022
Security, Defense, Technology, Other Technology, Networks, Other Defense, Government, Savannah State University Office of Graduate Studies and Sponsored Research, BAE Systems, U.S. Department of Defense Strategy for Operating in Cyberspace, Georgetown University Center for Latin American Studies, MIT Lincoln Laboratory, Artificial intelligence, Privacy Office of the U.S. Department of Homeland Security, Distinguished Fellow of the British Computer Society, Multimedia, Office of the Secretary of Defense, Security, Redwire, Science and technology in Asia, Leonardo DRS, Defence Medal, Research, Science, Dan Sullivan (U.S. senator), NASA Exceptional Public Service Medal, Under Secretary of Defense for Research and Engineering, Draper Laboratory, Belcan, Science and technology, DARPA, Management, Defense, DRS

Leonardo DRS, Inc. (Nasdaq: DRS) announced today the appointment of Dr. Louis Reginald “Reggie” Brothers to the company’s Board of Directors.

Key Points: 
  • Leonardo DRS, Inc. (Nasdaq: DRS) announced today the appointment of Dr. Louis Reginald “Reggie” Brothers to the company’s Board of Directors.
  • “We are very pleased to have Reggie join our Board of Directors.
  • He currently serves on the Board of Directors of AE Industrial Partners portfolio companies: American Pacific Corporation and Redwire.
  • From 2011 to 2014, Dr. Brothers served as Deputy Assistant Secretary of Defense for Research at the Department of Defense.

11th Chief Medical Officer Summit 360° Agenda and Keynotes Announced from The Conference Forum

Retrieved on: 
Thursday, December 15, 2022
Therapy, Alnylam Pharmaceuticals, Ecosystem, Chief Medical Officer (Ireland), Conference, Patient, Drug development, CMOS, CMO, Savannah State University Office of Graduate Studies and Sponsored Research, MBA, Pharmaceutical industry, Fine chemical, Management

NEW YORK, Dec. 15, 2022 /PRNewswire-PRWeb/ -- The Conference Forum is pleased to announce the agenda and keynote speakers for the 11th annual Chief Medical Officer Summit 360°, the only conference dedicated to supporting the role of the Chief Medical Officer in emerging biotechs. The CMO Summit 360° will take place in Boston on April 4-5.

Key Points: 
  • The Conference Forum is pleased to announce the agenda and keynote speakers for the 11th annual Chief Medical Officer Summit 360, the only conference dedicated to supporting the role of the Chief Medical Officer in emerging biotechs.
  • NEW YORK, Dec. 15, 2022 /PRNewswire-PRWeb/ -- The Conference Forum is pleased to announce the agenda and keynote speakers for the 11th annual Chief Medical Officer Summit 360, the only conference dedicated to supporting the role of the Chief Medical Officer in emerging biotechs.
  • The CMO Summit 360 will take place in Boston on April 4-5.
  • "The two-day CMO Summit has over 60 biotech Chief Medical Officers speaking in over 40 sessions.

DeepPower Announces R&D Program with the University of Oklahoma to Develop Its Breakthrough Geothermal Drilling Technology

Retrieved on: 
Tuesday, November 29, 2022
Farm, Pleasure, University, Associate professor, Wind, Savannah State University Office of Graduate Studies and Sponsored Research, Petroleum engineering, Research, Sun, Motivation, Human, Oil, Renewable energy, Online shopping, LEHI

Andrew Van Noy, CEO of DeepPower commented, We are thrilled to be able to enter into this relationship with a prestigious University such as the University of Oklahoma.

Key Points: 
  • Andrew Van Noy, CEO of DeepPower commented, We are thrilled to be able to enter into this relationship with a prestigious University such as the University of Oklahoma.
  • That passion coupled with his background was what led me to believe he would be a great partner on our joint quest to develop new geothermal drilling technologies.
  • DeepPower is developing a suite of breakthrough drilling technologies to boldly go where no humans have gone before.
  • For more information about DeepPower, Inc., please visit our website at www.DeepPower.com
    Deep Power is developing a breakthrough drilling technology to access Earths unlimited source of green geothermal energy.

Aspira Women’s Health Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Protein, Marketing, Investment, Leadership, Chief executive officer, Acceleration, Eastern Time Zone, Medical University of Łódź, Research, Intention, Urology, MicroRNA, Savannah State University Office of Graduate Studies and Sponsored Research, Hospital, Co-marketing, CFO, Conference, Medical school, Endometriosis, Ovarian cancer, Growth, Woman, Highlight, Employment, Conference call, Pharmaceutical industry, Life insurance, Health insurance, Video game, Animal, Aspira

ET

Key Points: 
  • ET
    AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira) (Nasdaq: AWH), a bio-analytical based womens health company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2022.
  • Ms. Sandford continued, On the innovation side, we reiterate our intention to launch OvaWatch in the fourth quarter of 2022.
  • Highlights of Third Quarter 2022 vs. Second Quarter 2022
    Product revenue was $2,037,000 for the three months ended September 30, 2022, compared to $2,018,000 for the three months ended June 30, 2022, an increase of 1%.
  • Aspira raised $9 million gross proceeds in a public offering during the third quarter of 2022.

Argus Updates Equity Research Report Coverage on Dogness (DOGZ)

Retrieved on: 
Friday, July 29, 2022
Chewy (company), Investment, View, COVID-19, Savannah State University Office of Graduate Studies and Sponsored Research, Industry, Research, Argus, OEM, U.S. Securities and Exchange Commission, Walmart, Cat, Private Securities Litigation Reform Act, Securities Act of 1933, Health, Research report, PETS, IKEA, Multimedia, NASDAQ, Technology, Company, Security (finance), COVID, Equity, Target, Petco, International, Amazon, Growth, Dog food, Dog, Pharmaceutical industry, Animal

DONGGUAN, China, July 29, 2022 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that Argus Research, an investment research firm retained by Dogness, updated its Equity Research Report coverage on Dogness.

Key Points: 
  • DONGGUAN, China, July 29, 2022 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that Argus Research, an investment research firm retained by Dogness, updated its Equity Research Report coverage on Dogness.
  • Dogness achieved 27% revenue growth in fiscal 2021, and 48% growth in the first half of fiscal 2022, despite macro-economic and COVID-related headwinds.
  • Argus Research Co. has received a flat fee from Dogness as part of a Sponsored Research agreement between Argus and the company.
  • No part of Argus Research's compensation is directly or indirectly related to the content of its assessment or to other opinions expressed in its research report.

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022
Department, Financial compensation, FDA, CF, Mutation, Science, University of Chicago, Patient, Savannah State University Office of Graduate Studies and Sponsored Research, Kidney, CEO, Massachusetts Institute of Technology, United States Attorney General, GLOBE, Â, European Commission, CFA, Degenerative disease, Cancer, Initial public offering, RMAS, Eukaryotic ribosome, MBA, Department of Human Services and Health, Fast Track, Orphan, Humanitarian use licenses, Food, Autosome, BS, Royal commission, Roivant Sciences, RNA, Psoriasis, Polycystic kidney disease, University, Cystic fibrosis, Acquisition, JD, Regulation of tobacco by the U.S. Food and Drug Administration, Overactive bladder, NASDAQ, Uterine fibroid, Management, Pharmaceutical industry

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.

Argus Updates Equity Research Report Coverage on Dogness (DOGZ)

Retrieved on: 
Friday, April 22, 2022
COVID-19, OEM, Savannah State University Office of Graduate Studies and Sponsored Research, Dog, Equity, U.S. Securities and Exchange Commission, Security (finance), NASDAQ, Research, International, Private Securities Litigation Reform Act, IKEA, Target, Securities Act of 1933, Growth, Technology, Cat, Company, Research report, Argus, PETS, Petco, Walmart, Dog food, Chewy (company), Investment, Amazon, Industry, Multimedia, Risk, Health, Semiconductor Manufacturing International Corporation, View, Pharmaceutical industry, Animal

PLANO, Texas, April 22, 2022 /PRNewswire/ --Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that Argus Research, an investment research firm, updated its Equity Research Report coverage on Dogness.

Key Points: 
  • PLANO, Texas, April 22, 2022 /PRNewswire/ --Dogness (International) Corporation ("Dogness" or the "Company") (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that Argus Research, an investment research firm, updated its Equity Research Report coverage on Dogness.
  • Argus Research Co. has received a flat fee from Dogness as part of a Sponsored Research agreement between Argus and the company.
  • No part of Argus Research's compensation is directly or indirectly related to the content of its assessment or to other opinions expressed in its research report.
  • Please refer to the full Argus report and the disclaimer for complete disclosures.

Argus Research Initiates Equity Research Report Coverage on Society Pass Inc. (NasdaqCM: SOPA)

Retrieved on: 
Monday, April 4, 2022
SOPA, S&P Global, Secondary research, FactSet, Behavior, Population, GMV, Russell, Restaurant, POS, Growth, Multimedia, EV, City, Loyalty, Thomson Reuters, Travel, Research, Argus, Theosophical Society Point Loma - Blavatskyhouse, The Beautiful Person, Bloomberg, Stock, Bankruptcy, Food, Pushcart, GDP, Software, Lifestyle, Pittsburgh Food & Beverage Company, Ecosystem, Time, Equity, Nasdaq, Facebook, Savannah State University Office of Graduate Studies and Sponsored Research, International Monetary Fund, Digital media, Social media, IPO, South Korean IMF (International Monetary Fund) Agreement,1997, Financial services, Online shopping, Food delivery, Renewable energy, Mobile phone, Tutoring, EU

NEW YORK, April 4, 2022 /PRNewswire/ --Argus Research, an independent investment research firm, has launched Equity Research Report coverage on Society Pass Inc. (NasdaqCM: SOPA)

Key Points: 
  • NEW YORK, April 4, 2022 /PRNewswire/ --Argus Research, an independent investment research firm, has launched Equity Research Report coverage on Society Pass Inc. (NasdaqCM: SOPA)
    COMPANY HIGHLIGHTS: Excerpts (asconveyed by Argus Analyst Steve Silver) include:
    Society Pass is an e-commerce company operating in fast-growing Southeast Asian markets.
  • Society Pass plans to integrate these diverse businesses through a loyalty program called Society Points, which it will launch in 2Q.
  • In February 2022, Society Pass acquired Pushkart, a Philippines online grocery delivery app with its own fleet of delivery vehicles.
  • Argus's Equity Research & earnings estimates are available on major research / earnings estimate aggregator platforms, including Bloomberg, Thomson Reuters, Factset and S&P Global.